| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Scleroderma, Systemic | 30 | 2024 | 117 | 6.660 |
Why?
|
| Cadherins | 14 | 2024 | 172 | 5.540 |
Why?
|
| Lupus Erythematosus, Systemic | 8 | 2024 | 193 | 2.290 |
Why?
|
| Arthritis, Rheumatoid | 14 | 2024 | 261 | 2.120 |
Why?
|
| Macrophages | 5 | 2024 | 626 | 1.880 |
Why?
|
| Skin | 7 | 2024 | 521 | 1.580 |
Why?
|
| Antirheumatic Agents | 7 | 2023 | 120 | 1.470 |
Why?
|
| Autoantibodies | 11 | 2019 | 433 | 1.410 |
Why?
|
| Skin Diseases | 3 | 2018 | 129 | 1.190 |
Why?
|
| Autoimmune Diseases | 7 | 2024 | 252 | 1.190 |
Why?
|
| Pulmonary Fibrosis | 4 | 2022 | 109 | 1.170 |
Why?
|
| Genetic Predisposition to Disease | 16 | 2024 | 3176 | 1.170 |
Why?
|
| Transforming Growth Factor beta | 7 | 2019 | 465 | 1.160 |
Why?
|
| Fibroblasts | 11 | 2024 | 887 | 1.130 |
Why?
|
| Disease Models, Animal | 13 | 2024 | 4409 | 1.090 |
Why?
|
| Rheumatic Diseases | 5 | 2024 | 69 | 1.070 |
Why?
|
| Fibrosis | 9 | 2024 | 442 | 1.040 |
Why?
|
| Synovitis | 2 | 2020 | 25 | 0.950 |
Why?
|
| STAT3 Transcription Factor | 2 | 2018 | 218 | 0.950 |
Why?
|
| Lung Diseases, Interstitial | 6 | 2024 | 149 | 0.940 |
Why?
|
| Dendritic Cells | 3 | 2024 | 414 | 0.870 |
Why?
|
| Liver | 2 | 2022 | 1749 | 0.850 |
Why?
|
| Phagocytosis | 2 | 2024 | 171 | 0.850 |
Why?
|
| Extracellular Matrix | 4 | 2019 | 238 | 0.770 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2022 | 15 | 0.770 |
Why?
|
| Genome-Wide Association Study | 6 | 2024 | 1694 | 0.730 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2024 | 237 | 0.720 |
Why?
|
| Patient Compliance | 1 | 2024 | 471 | 0.700 |
Why?
|
| Kava | 1 | 2020 | 7 | 0.700 |
Why?
|
| Early Detection of Cancer | 1 | 2024 | 362 | 0.690 |
Why?
|
| Uveitis | 1 | 2020 | 36 | 0.690 |
Why?
|
| Sarcoidosis | 1 | 2020 | 61 | 0.670 |
Why?
|
| Arthritis | 1 | 2020 | 81 | 0.670 |
Why?
|
| Myofibroblasts | 3 | 2019 | 77 | 0.660 |
Why?
|
| Monocytes | 1 | 2022 | 345 | 0.650 |
Why?
|
| Rheumatology | 4 | 2024 | 119 | 0.650 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 73 | 0.650 |
Why?
|
| Osteoarthropathy, Primary Hypertrophic | 1 | 2019 | 2 | 0.640 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 3 | 2015 | 113 | 0.620 |
Why?
|
| Bleomycin | 7 | 2024 | 153 | 0.620 |
Why?
|
| Polymorphism, Single Nucleotide | 12 | 2017 | 2656 | 0.610 |
Why?
|
| Naphthols | 1 | 2018 | 7 | 0.610 |
Why?
|
| Medical History Taking | 1 | 2019 | 108 | 0.610 |
Why?
|
| Watchful Waiting | 1 | 2019 | 69 | 0.600 |
Why?
|
| Sulfonamides | 2 | 2024 | 270 | 0.570 |
Why?
|
| Antibodies, Monoclonal | 6 | 2017 | 1026 | 0.570 |
Why?
|
| Immunologic Factors | 2 | 2011 | 173 | 0.570 |
Why?
|
| Mice | 20 | 2024 | 17750 | 0.560 |
Why?
|
| Humans | 69 | 2024 | 125356 | 0.540 |
Why?
|
| Autoimmunity | 2 | 2024 | 172 | 0.530 |
Why?
|
| Animals | 25 | 2024 | 34319 | 0.530 |
Why?
|
| Lung Diseases, Parasitic | 1 | 2016 | 14 | 0.510 |
Why?
|
| Strongyloides stercoralis | 1 | 2016 | 23 | 0.510 |
Why?
|
| Strongyloidiasis | 1 | 2016 | 43 | 0.500 |
Why?
|
| Pulmonary Alveoli | 1 | 2016 | 134 | 0.480 |
Why?
|
| Mice, Knockout | 8 | 2024 | 3754 | 0.470 |
Why?
|
| Cell Differentiation | 3 | 2022 | 1909 | 0.470 |
Why?
|
| Inflammation | 3 | 2024 | 1445 | 0.450 |
Why?
|
| Cell Adhesion | 4 | 2022 | 347 | 0.400 |
Why?
|
| Hypertension, Pulmonary | 3 | 2023 | 439 | 0.400 |
Why?
|
| Hemorrhage | 1 | 2016 | 467 | 0.400 |
Why?
|
| Liver Cirrhosis | 1 | 2019 | 859 | 0.390 |
Why?
|
| Cytokines | 6 | 2019 | 1291 | 0.380 |
Why?
|
| HLA Antigens | 4 | 2024 | 238 | 0.380 |
Why?
|
| Rheumatoid Factor | 1 | 2011 | 5 | 0.380 |
Why?
|
| Osteopontin | 1 | 2012 | 48 | 0.380 |
Why?
|
| Mice, Inbred C57BL | 10 | 2024 | 4423 | 0.380 |
Why?
|
| Managed Care Programs | 1 | 2011 | 61 | 0.370 |
Why?
|
| CD58 Antigens | 1 | 2011 | 7 | 0.360 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2011 | 18 | 0.360 |
Why?
|
| CD11b Antigen | 1 | 2011 | 36 | 0.360 |
Why?
|
| CD11c Antigen | 1 | 2011 | 38 | 0.360 |
Why?
|
| Epithelial Cells | 1 | 2015 | 910 | 0.350 |
Why?
|
| Female | 32 | 2024 | 66820 | 0.340 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2011 | 217 | 0.340 |
Why?
|
| Genetic Loci | 2 | 2011 | 342 | 0.340 |
Why?
|
| Severity of Illness Index | 5 | 2017 | 2909 | 0.340 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2009 | 21 | 0.330 |
Why?
|
| OX40 Ligand | 1 | 2009 | 8 | 0.330 |
Why?
|
| Receptors, Interleukin | 1 | 2009 | 33 | 0.330 |
Why?
|
| Male | 34 | 2024 | 61565 | 0.320 |
Why?
|
| Interferon-alpha | 1 | 2011 | 241 | 0.310 |
Why?
|
| Cells, Cultured | 6 | 2019 | 3044 | 0.310 |
Why?
|
| Lung | 2 | 2015 | 1491 | 0.300 |
Why?
|
| Synovial Fluid | 1 | 2008 | 15 | 0.300 |
Why?
|
| Myositis | 2 | 2024 | 61 | 0.290 |
Why?
|
| Cell Communication | 2 | 2008 | 167 | 0.290 |
Why?
|
| Withholding Treatment | 1 | 2008 | 68 | 0.290 |
Why?
|
| Stress, Psychological | 2 | 2011 | 550 | 0.290 |
Why?
|
| Middle Aged | 18 | 2024 | 26763 | 0.280 |
Why?
|
| Glucocorticoids | 3 | 2024 | 384 | 0.270 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2010 | 682 | 0.260 |
Why?
|
| Interferon Regulatory Factor-7 | 2 | 2019 | 7 | 0.260 |
Why?
|
| Antigens, CD | 1 | 2008 | 430 | 0.250 |
Why?
|
| Hospitals, University | 1 | 2005 | 98 | 0.250 |
Why?
|
| Cell Adhesion Molecules | 1 | 2006 | 231 | 0.230 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2024 | 11 | 0.220 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 3407 | 0.220 |
Why?
|
| Phagocytes | 1 | 2024 | 23 | 0.220 |
Why?
|
| Terpenes | 1 | 2024 | 28 | 0.220 |
Why?
|
| Myeloid Cells | 1 | 2024 | 102 | 0.210 |
Why?
|
| Lipoblastoma | 1 | 2023 | 6 | 0.210 |
Why?
|
| B-Lymphocytes | 2 | 2019 | 532 | 0.210 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2019 | 325 | 0.210 |
Why?
|
| Adult | 16 | 2024 | 29543 | 0.210 |
Why?
|
| Liposomes | 1 | 2024 | 188 | 0.210 |
Why?
|
| Genotype | 6 | 2011 | 2570 | 0.210 |
Why?
|
| Macrophages, Alveolar | 2 | 2014 | 49 | 0.210 |
Why?
|
| Dermatologic Agents | 1 | 2023 | 31 | 0.200 |
Why?
|
| Collagen | 3 | 2019 | 317 | 0.200 |
Why?
|
| Psoriasis | 1 | 2023 | 46 | 0.200 |
Why?
|
| Antigens, Ly | 1 | 2022 | 34 | 0.190 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2023 | 122 | 0.190 |
Why?
|
| Antibodies, Antinuclear | 2 | 2011 | 28 | 0.180 |
Why?
|
| Biological Products | 1 | 2023 | 123 | 0.180 |
Why?
|
| Sweet Syndrome | 1 | 2021 | 10 | 0.180 |
Why?
|
| Myoclonus | 1 | 2021 | 32 | 0.180 |
Why?
|
| Polymorphism, Genetic | 1 | 2024 | 819 | 0.180 |
Why?
|
| Signal Transduction | 7 | 2019 | 4595 | 0.180 |
Why?
|
| Vitamin D | 2 | 2019 | 165 | 0.170 |
Why?
|
| Encephalitis | 1 | 2021 | 109 | 0.170 |
Why?
|
| Glomerulonephritis | 1 | 2020 | 74 | 0.170 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 407 | 0.160 |
Why?
|
| Carbon Tetrachloride | 1 | 2019 | 6 | 0.160 |
Why?
|
| Hepatic Stellate Cells | 1 | 2019 | 21 | 0.160 |
Why?
|
| Cohort Studies | 6 | 2017 | 4828 | 0.160 |
Why?
|
| Disease Progression | 4 | 2024 | 2084 | 0.160 |
Why?
|
| Case-Control Studies | 7 | 2023 | 3313 | 0.160 |
Why?
|
| Iron, Dietary | 1 | 2019 | 16 | 0.160 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 2018 | 3 | 0.150 |
Why?
|
| Vitamins | 1 | 2019 | 108 | 0.150 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2024 | 732 | 0.150 |
Why?
|
| Hepatocytes | 1 | 2019 | 210 | 0.140 |
Why?
|
| Bone Neoplasms | 1 | 2022 | 427 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 855 | 0.140 |
Why?
|
| Nanoparticles | 1 | 2020 | 230 | 0.140 |
Why?
|
| Receptors, Calcitriol | 1 | 2017 | 70 | 0.140 |
Why?
|
| Apoptosis | 1 | 2024 | 1818 | 0.140 |
Why?
|
| Arthralgia | 1 | 2017 | 56 | 0.140 |
Why?
|
| Ustekinumab | 1 | 2017 | 2 | 0.140 |
Why?
|
| Aromatase Inhibitors | 1 | 2017 | 76 | 0.140 |
Why?
|
| Chemokine CCL2 | 1 | 2017 | 125 | 0.130 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 162 | 0.130 |
Why?
|
| Synovial Membrane | 2 | 2007 | 27 | 0.130 |
Why?
|
| Gene Expression Profiling | 4 | 2010 | 1756 | 0.130 |
Why?
|
| Dermis | 2 | 2016 | 24 | 0.130 |
Why?
|
| Up-Regulation | 3 | 2019 | 875 | 0.120 |
Why?
|
| Biomarkers | 5 | 2022 | 3106 | 0.120 |
Why?
|
| Mice, 129 Strain | 2 | 2014 | 97 | 0.120 |
Why?
|
| Methotrexate | 3 | 2023 | 336 | 0.120 |
Why?
|
| Histocompatibility Antigens Class II | 3 | 2011 | 84 | 0.120 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2014 | 42 | 0.110 |
Why?
|
| United States | 7 | 2024 | 10908 | 0.110 |
Why?
|
| Prognosis | 3 | 2019 | 4686 | 0.110 |
Why?
|
| Platelet Factor 4 | 1 | 2013 | 22 | 0.110 |
Why?
|
| Biopsy | 1 | 2017 | 1244 | 0.110 |
Why?
|
| Child | 3 | 2024 | 24613 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2010 | 1033 | 0.110 |
Why?
|
| Young Adult | 2 | 2024 | 9061 | 0.110 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 1550 | 0.110 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2014 | 158 | 0.100 |
Why?
|
| Epistasis, Genetic | 2 | 2010 | 94 | 0.100 |
Why?
|
| Treatment Failure | 2 | 2017 | 338 | 0.100 |
Why?
|
| Transcriptome | 1 | 2019 | 977 | 0.100 |
Why?
|
| Interleukin-6 | 1 | 2014 | 421 | 0.100 |
Why?
|
| Interferon Regulatory Factors | 1 | 2012 | 37 | 0.100 |
Why?
|
| Smad2 Protein | 1 | 2012 | 50 | 0.100 |
Why?
|
| Receptors, Interleukin-12 | 1 | 2011 | 9 | 0.100 |
Why?
|
| Genetic Markers | 2 | 2011 | 605 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 128 | 0.090 |
Why?
|
| Stress Disorders, Traumatic | 1 | 2011 | 5 | 0.090 |
Why?
|
| Adolescent | 4 | 2024 | 19429 | 0.090 |
Why?
|
| Histocompatibility Testing | 2 | 2009 | 144 | 0.090 |
Why?
|
| France | 1 | 2011 | 80 | 0.090 |
Why?
|
| Neurosecretory Systems | 1 | 2011 | 23 | 0.090 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2010 | 8 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 1961 | 0.090 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2010 | 20 | 0.090 |
Why?
|
| Cell Movement | 1 | 2014 | 854 | 0.090 |
Why?
|
| Societies, Medical | 2 | 2024 | 700 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2023 | 12287 | 0.080 |
Why?
|
| STAT4 Transcription Factor | 1 | 2009 | 7 | 0.080 |
Why?
|
| Interleukin-23 | 1 | 2009 | 12 | 0.080 |
Why?
|
| CD3 Complex | 1 | 2010 | 91 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 231 | 0.080 |
Why?
|
| Drug Therapy, Combination | 2 | 2023 | 1172 | 0.080 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2010 | 138 | 0.080 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2011 | 212 | 0.080 |
Why?
|
| Centromere | 1 | 2009 | 108 | 0.080 |
Why?
|
| Epidemiologic Methods | 1 | 2009 | 108 | 0.080 |
Why?
|
| Genetic Association Studies | 2 | 2010 | 779 | 0.080 |
Why?
|
| src-Family Kinases | 1 | 2009 | 91 | 0.080 |
Why?
|
| Interferons | 1 | 2010 | 126 | 0.080 |
Why?
|
| Interleukin-17 | 1 | 2009 | 121 | 0.080 |
Why?
|
| Leukocytes | 2 | 2010 | 212 | 0.080 |
Why?
|
| T-Box Domain Proteins | 1 | 2009 | 115 | 0.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 508 | 0.080 |
Why?
|
| Linkage Disequilibrium | 1 | 2009 | 309 | 0.080 |
Why?
|
| Social Support | 1 | 2011 | 340 | 0.080 |
Why?
|
| Antigens, CD1 | 1 | 2008 | 21 | 0.080 |
Why?
|
| Mass Screening | 2 | 2024 | 785 | 0.070 |
Why?
|
| Antigen Presentation | 1 | 2008 | 104 | 0.070 |
Why?
|
| Alleles | 2 | 2011 | 1618 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 2182 | 0.070 |
Why?
|
| Lymphocyte Activation | 1 | 2010 | 700 | 0.070 |
Why?
|
| Molecular Sequence Data | 2 | 2010 | 3900 | 0.070 |
Why?
|
| Risk Factors | 4 | 2011 | 10298 | 0.070 |
Why?
|
| Epitopes | 1 | 2009 | 433 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 825 | 0.070 |
Why?
|
| Multiple Sclerosis | 1 | 2010 | 324 | 0.070 |
Why?
|
| Family | 1 | 2010 | 562 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1703 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 1104 | 0.070 |
Why?
|
| Mutation | 1 | 2020 | 5905 | 0.070 |
Why?
|
| Aged | 6 | 2024 | 19722 | 0.070 |
Why?
|
| Adherens Junctions | 1 | 2006 | 15 | 0.070 |
Why?
|
| Cell Line | 1 | 2011 | 2756 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2023 | 16369 | 0.060 |
Why?
|
| Recurrence | 2 | 2010 | 1394 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2023 | 1634 | 0.060 |
Why?
|
| Health Status | 1 | 2008 | 375 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2023 | 509 | 0.060 |
Why?
|
| Massachusetts | 1 | 2005 | 125 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2024 | 2096 | 0.060 |
Why?
|
| Infliximab | 1 | 2005 | 66 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 2520 | 0.060 |
Why?
|
| Treatment Refusal | 1 | 2005 | 78 | 0.060 |
Why?
|
| Vital Capacity | 2 | 2017 | 76 | 0.060 |
Why?
|
| Lipids | 1 | 2008 | 522 | 0.060 |
Why?
|
| Peptides | 1 | 2008 | 812 | 0.060 |
Why?
|
| rho-Associated Kinases | 2 | 2016 | 53 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2022 | 6141 | 0.060 |
Why?
|
| Gene Frequency | 3 | 2011 | 729 | 0.060 |
Why?
|
| T-Lymphocytes | 2 | 2010 | 1720 | 0.060 |
Why?
|
| Mixed Connective Tissue Disease | 1 | 2024 | 2 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 1269 | 0.060 |
Why?
|
| Phenotype | 2 | 2011 | 4270 | 0.060 |
Why?
|
| Drug Utilization | 1 | 2005 | 161 | 0.060 |
Why?
|
| Walk Test | 1 | 2024 | 24 | 0.060 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2008 | 383 | 0.060 |
Why?
|
| Aniline Compounds | 1 | 2024 | 19 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 730 | 0.060 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2011 | 623 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2024 | 198 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 173 | 0.050 |
Why?
|
| Mesentery | 1 | 2023 | 27 | 0.050 |
Why?
|
| Health Care Surveys | 1 | 2024 | 283 | 0.050 |
Why?
|
| Sjogren's Syndrome | 1 | 2024 | 87 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 88 | 0.050 |
Why?
|
| Drug Prescriptions | 1 | 2024 | 221 | 0.050 |
Why?
|
| Blood Sedimentation | 1 | 2022 | 29 | 0.050 |
Why?
|
| Truth Disclosure | 1 | 2003 | 102 | 0.050 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2022 | 100 | 0.050 |
Why?
|
| Tuberculosis | 1 | 2008 | 527 | 0.050 |
Why?
|
| Tretinoin | 1 | 2022 | 118 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 1692 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 2525 | 0.050 |
Why?
|
| Osteoblasts | 1 | 2022 | 150 | 0.050 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2020 | 16 | 0.040 |
Why?
|
| Lymphatic System | 1 | 2020 | 20 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2024 | 630 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2024 | 469 | 0.040 |
Why?
|
| Europe | 2 | 2011 | 359 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2022 | 359 | 0.040 |
Why?
|
| Physician-Patient Relations | 1 | 2003 | 429 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2020 | 145 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2022 | 433 | 0.040 |
Why?
|
| Receptors, Interleukin-15 | 1 | 2019 | 2 | 0.040 |
Why?
|
| Smad3 Protein | 1 | 2019 | 58 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2023 | 645 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2022 | 502 | 0.040 |
Why?
|
| Mastectomy | 1 | 2017 | 64 | 0.040 |
Why?
|
| Androstadienes | 1 | 2017 | 50 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2019 | 284 | 0.030 |
Why?
|
| Physicians | 1 | 2003 | 588 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 89 | 0.030 |
Why?
|
| Canada | 1 | 2017 | 286 | 0.030 |
Why?
|
| Tensile Strength | 1 | 2016 | 40 | 0.030 |
Why?
|
| Elastic Modulus | 1 | 2016 | 28 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 366 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 371 | 0.030 |
Why?
|
| Elastin | 1 | 2016 | 31 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2016 | 243 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 367 | 0.030 |
Why?
|
| Fibronectins | 1 | 2014 | 110 | 0.030 |
Why?
|
| Feedback, Physiological | 1 | 2014 | 69 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 670 | 0.030 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2013 | 20 | 0.030 |
Why?
|
| Muscle Development | 1 | 2014 | 69 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1362 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1320 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2014 | 129 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 2014 | 188 | 0.030 |
Why?
|
| Nanotechnology | 1 | 2013 | 46 | 0.030 |
Why?
|
| Peptides, Cyclic | 1 | 2013 | 55 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2014 | 626 | 0.030 |
Why?
|
| Urinary Bladder | 1 | 2014 | 244 | 0.030 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2014 | 231 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2016 | 801 | 0.020 |
Why?
|
| Proteome | 1 | 2013 | 246 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 3605 | 0.020 |
Why?
|
| Immunogenetics | 1 | 2011 | 8 | 0.020 |
Why?
|
| HLA-DRB1 Chains | 1 | 2011 | 38 | 0.020 |
Why?
|
| Models, Biological | 1 | 2016 | 1465 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2013 | 288 | 0.020 |
Why?
|
| Age of Onset | 1 | 2012 | 601 | 0.020 |
Why?
|
| Ribonucleoprotein, U1 Small Nuclear | 1 | 2010 | 2 | 0.020 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2010 | 10 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 1284 | 0.020 |
Why?
|
| Spain | 1 | 2009 | 60 | 0.020 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2009 | 31 | 0.020 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2010 | 105 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2009 | 79 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 1554 | 0.020 |
Why?
|
| Th2 Cells | 1 | 2009 | 185 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2009 | 153 | 0.020 |
Why?
|
| Biological Transport, Active | 1 | 2008 | 87 | 0.020 |
Why?
|
| Phagosomes | 1 | 2008 | 36 | 0.020 |
Why?
|
| Infant | 1 | 2023 | 12602 | 0.020 |
Why?
|
| Haplotypes | 1 | 2009 | 521 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 1495 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2023 | 14149 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2013 | 2813 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2009 | 462 | 0.020 |
Why?
|
| Arthritis, Experimental | 1 | 2007 | 15 | 0.020 |
Why?
|
| Comorbidity | 1 | 2012 | 1528 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 2050 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 1253 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2007 | 154 | 0.020 |
Why?
|
| Vinculin | 1 | 2006 | 4 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 6558 | 0.020 |
Why?
|
| Reticulin | 1 | 2006 | 8 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2008 | 464 | 0.020 |
Why?
|
| Kinetics | 1 | 2008 | 1333 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2006 | 67 | 0.020 |
Why?
|
| Registries | 1 | 2012 | 1434 | 0.020 |
Why?
|
| Transfection | 1 | 2006 | 1076 | 0.010 |
Why?
|
| Actins | 1 | 2006 | 345 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2010 | 1505 | 0.010 |
Why?
|
| Affect | 1 | 2003 | 156 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 5171 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2003 | 1017 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2003 | 327 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2003 | 1377 | 0.010 |
Why?
|
| Texas | 1 | 2003 | 3581 | 0.010 |
Why?
|
| Neoplasms | 1 | 2003 | 2799 | 0.000 |
Why?
|